Pharmacokinetic and pharmacodynamic interactions between recombinant human luteinizing hormone and recombinant human follicle-stimulating hormone

Fertility and Sterility

Volumn 69, Issue 2, 1998, Pages 201-209

  Le Cotonnec, Jean Yves ^a,b   Loumaye, Ernest ^a   Porchet, Hervé Claude ^a,b   Beltrami, Vanya ^a   Munafo, Alain ^a  

^a Serono International SA   (Switzerland)

^b Triskel Consulting   (Switzerland)

Author keywords

Immunoassay; Interaction; Pharmacokinetics; Recombinant human FSH; Recombinant human LH

Indexed keywords

LUTEINIZING HORMONE; RECOMBINANT FOLLITROPIN; RECOMBINANT LUTEINIZING HORMONE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DRUG ABSORPTION; DRUG HALF LIFE; DRUG POTENTIATION; FEMALE; FOLLITROPIN BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; LUTEINIZING HORMONE BLOOD LEVEL; NORMAL HUMAN; OVARY FOLLICLE MATURATION; OVARY HYPERSTIMULATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STEROIDOGENESIS; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; CROSS-OVER STUDIES; DRUG COMBINATIONS; ESTRADIOL; FEMALE; FOLLICLE STIMULATING HORMONE; GONADOTROPIN-RELEASING HORMONE; GOSERELIN; HALF-LIFE; HUMANS; INHIBINS; INJECTIONS, SUBCUTANEOUS; LUTEINIZING HORMONE; OVARIAN FOLLICLE; PITUITARY GLAND; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; TIME FACTORS;

EID: 0031931057     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0015-0282(97)00503-7     Document Type: Article

References (21)

1. Le Cotonnec J-Y, Porchet HC, Beltrami V, Kahn A, Toon S, Rowland M. Clinical pharmacology of recombinant follicle stimulating hormone: Part I: Comparative pharmacokinetics with urinary FSH. Fertil Steril 1994;61:669-78.
2. Le Cotonnec J-Y, Porchet HC, Beltrami V, Kahn A, Toon S, Rowland M. Clinical Pharmacology of recombinant human follicle-stimulating hormone (FSH). Part II. Single dose and steady-state pharmacokinetics. Fertil Steril 1994;61:679-86.
3. Porchet HC, Loumaye E, Le Cotonnec J-Y. Clinical pharmacology of recombinant human follicle-stimulating hormone (FSH). Part III. Pharmacokinetic-pharmacodynamic modeling after repeated subcutaneous administration. Fertil Steril 1994;61:687-95.
4. Le Cotonnec J-Y, Porchet HC, Beltrami V, Munafo A. Clinical pharmacology of recombinant human luteinizing hormone. Part I: Pharmacokinetics after intravenous administration to healthy female volunteers and comparison with urinary human luteinizing hormone. Fertil Steril 1998;69:189-94.
5. Le Cotonnec J-Y, Porchet HC, Beltrami V, Munafo A. Clinical pharmacology of recombinant human luteinizing hormone: Part II: Bioavailability of recombinant human luteinizing hormone in humans assessed with an immunoassay and an in vitro bioassay. Fertil Steril 1998;69:195-200.
6. Ben-Chetrit A, Gotlieb L, Wong PY, Casper RF. Ovarian response to recombinant human-follicle stimulating hormone in luteinizing hormone-depleted women: examination of the two cell, two gonadotropin theory. Fertil Steril 1996;65:711-7.
7. Zelinski-Wooten M, Hutchison J, Hess D, Wolf D, Stouffer R. Follicle stimulating hormone alone supports follicle growth and oocyte development in gonadotrophin-releasing hormone antagonist-treated monkeys. Hum Reprod 1995;10:1658-66.
8. Daya S, Gunby J, Hughes EG, Collins JA, Sagle MA. Follicle-stimulating hormone versus human menopausal gonadotropin for in vitro fertilization cycles: a meta-analysis. Fertil Steril 1995;64:347-54.
9. Couzinet B, Lestrat N, Barilly S, Forest M, Schaison G. Stimulation of ovarian follicular maturation with pure follicle-stimulating hormone in women with gonadotropin deficiency. J Clin Endocrinol Metab 1988;66:552-6.
10. Shohan Z, Balen A, Patel A, Jacobs HS. HMG versus purified FSH in hypogonadism. Fertil Steril 1991;56:1048-53.
11. Hull M, Corrigan E, Piazzi A, Loumaye E. Recombinant human luteinising hormone: an effective new gonadotropin preparation. Lancet 1994;344:334-5.
12. Van Hell H, Matthijsen R, Overbeek GA. Effects of menopausal gonadotrophin preparations in different bioassay methods. Acta Endocrinol 1964;47:409-18.
13. Steelman SL, Pohley FM. Assay of follicle-stimulating hormone based on augmentation with human chorionic gonadotropin. Endocrinol 1953;53:604-16.
14. Dahl K, Stone M. FSH isoforms, radioimmunoassays, bioassays and their significance. Androl 1992;13:11-22.
15. Schneyer AL, Mason AJ, Burton LE, Zegner JR, Crowley WF. Immunoreactive inhibin α-subunit in human serum: implications for radioimmunoassay. J Clin Endocrinol Metab 1990;70:1208-12.
16. Poncelet E, Eliard P. Construction of a sensitive two-site immunozymatic assay for human inhibin in serum and other biological fluids. Hum Reprod 1990;5:110.
17. Gibaldi M, Perrier D. Pharmacokinetics. 2nd ed. New York: Marcel Dekker, 1982.
18. Holford NHG, Sheiner LB. Understanding the dose-effect relationship: Clinical application of pharmacokinetic-pharmacodynamic models. Clin Pharmacokinet 1981;6:429-53.
19. Le Cotonnec J-Y, Porchet HC. Comparative pharmacokinetics in monkeys of pituitary, urinary and recombinant human LH. In: Emperaire JC, editor. The triggering of ovulation in stimulated cycles: hCG or LH? Carnforth: Parthenon Publishing Group, 1994;145-54.
20. Le Cotonnec J-Y, Porchet HC, Beltrami V, Howles C. Comparative pharmacokinetics of two urinary human follicle-stimulating hormone preparations in healthy female and male volunteers. Hum Reprod 1993;8:1604-11.
21. Le Cotonnec J-Y, Porchet HC, Beltrami V, Kahn A, Toon S, Rowland M. Comprehensive pharmacokinetics of human follicle stimulating hormone in healthy female volunteers. Pharmaceut Res 1995;12:6844-50.